Biophytis S.A. (0D1W.L)
LSE · EUR
€0.0343 (-2.00%) as of
Key statistics
- EPS (TTM)
- -0.2640
- 52-week range
- 0.0036 – 0.0518
- Beta
- 1.71
- Profit margin
- 0.00%
- Volume
- 711.00
About Biophytis S.A.
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It also has an alliance with LynxKite Technologies Pte Ltd for the development of AI-driven drug discovery for longevity therapies. The company was incorporated in 2006 and is headquartered in Paris, France.
- Headquarters
- Paris, France
- Employees
- 19
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.